New drug combo shows promise in Hard-to-Treat cancers

NCT ID NCT03875820

First seen Mar 20, 2026 · Last updated Jun 13, 2026 · Updated 12 times

Summary

This early-phase trial tests two experimental drugs, defactinib and VS-6766, together in people with advanced solid tumors that have stopped responding to standard treatments. The study includes patients with certain lung, ovarian, endometrial, and pancreatic cancers. The main goals are to find the safest dose and to check how well the combination controls the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • The Christie NHS Foundation Trust

    Manchester, Greater Manchester, M20 4BX, United Kingdom

  • The Newcastle Upon Tyne Hospitals NHS Foundation Trust - Freeman Hospital

    Newcastle, NE7 7DN, United Kingdom

  • The Royal Marsden NHS Foundation Trust

    Sutton, Surrey, SM2 5PT, United Kingdom

  • The Royal Marsden NHS Foundation Trust - Gynecology Unit

    London, SW3 6JJ, United Kingdom

  • The Royal Marsden NHS Foundation Trust - Gynecology Unit

    Sutton, SM2 5PT, United Kingdom

Conditions

Explore the condition pages connected to this study.